首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Integration of Different -omics Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells
【2h】

Integration of Different -omics Technologies Identifies Inhibition of the IGF1R-Akt-mTOR Signaling Cascade Involved in the Cytotoxic Effect of Shikonin against Leukemia Cells

机译:整合不同的组学技术可确定IGF1R-Akt-mTOR信号级联的抑制作用该信号级联涉及紫草素对白血病细胞的细胞毒性作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hematological malignancies frequently have a poor prognosis and often remain incurable. Drug resistance, severe side effects, and relapse are major problems of currently used drugs, and new candidate compounds are required for improvement of therapy success. The naphthoquinone shikonin derived from the Chinese medicinal herb, Lithospermum erythrorhizon, is a promising candidate for the next generation of chemotherapy. The basal cellular mechanism of shikonin is the direct targeting of mitochondria. Cytotoxicity screenings showed that the compound is particularly effective against leukemia cells suggesting an additional cellular mechanism. mRNA and miRNA microarrays were used to analyze changes in gene expression in leukemia cells after shikonin treatment and combined with stable-isotope dimethyl labeling for quantitative proteomics. The integration of bioinformatics and the three “-omics” assays showed that the PI3K-Akt-mTOR pathway was affected by shikonin. Deregulations of this pathway are frequently associated with cancerogenesis, especially in a wide range of hematological malignancies. The effect on the PI3K-Akt-mTOR axis was validated by demonstrating a decreased phosphorylation of Akt and a direct inhibition of the IGF1R kinase activity after shikonin treatment. Our results indicate that inhibiting the IGF1R-Akt-mTOR signaling cascade is a new cellular mechanism of shikonin strengthening its potential for the treatment of hematological malignancies.
机译:血液系统恶性肿瘤的预后往往很差,并且常常无法治愈。耐药性,严重的副作用和复发是当前使用的药物的主要问题,并且需要新的候选化合物来改善治疗的成功。源自中草药紫草紫杉的萘醌紫草素是下一代化学疗法的有希望的候选者。紫草素的基础细胞机制是线粒体的直接靶向。细胞毒性筛选显示该化合物对白血病细胞特别有效,表明存在其他细胞机制。 mRNA和miRNA芯片用于分析紫草素处理后白血病细胞中基因表达的变化,并与稳定同位素二甲基标记结合用于定量蛋白质组学。生物信息学和三种“ -omics”检测方法的整合表明,紫草素影响了PI3K-Akt-mTOR途径。该途径的失调通常与癌症发生有关,尤其是在广泛的血液系统恶性肿瘤中。通过证实紫草素处理后,Akt的磷酸化降低和对IGF1R激酶活性的直接抑制,证实了对PI3K-Akt-mTOR轴的作用。我们的结果表明,抑制IGF1R-Akt-mTOR信号级联反应是紫草素增强其治疗血液系统恶性肿瘤潜力的新细胞机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号